RARS1 and neoplasm: As we saw such a robust anti-tumor response to the combination of tretinoin and CY in the AB1-HA model but not in models using other cell lines, we tested whether the expression of retinoic acid receptors (RARs) or retinoid X receptors (RXRs) varied between tumor models, as a potential explanation of the differing outcomes.